Jazz Pharmaceuticals (JAZZ) Operating Leases (2019 - 2026)

Jazz Pharmaceuticals' Operating Leases history runs 8 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• In Q1 2026, Operating Leases rose 21.97% year-over-year to $47.3 million; the TTM figure through Mar 2026 stood at $47.3 million (up 21.97% YoY), while the FY2025 annual figure was $50.9 million, up 30.72% from the prior year.
• Operating Leases was $47.3 million for Q1 2026 at Jazz Pharmaceuticals, down from $50.9 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $83.1 million in Q1 2022 to a low of $38.8 million in Q1 2025.
• Historically, Operating Leases has averaged $61.4 million across 5 years, with a median of $61.9 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Operating Leases tumbled 56.03% in 2022, then soared 30.72% in 2025.
• A 5-year view of Operating Leases shows it stood at $71.8 million in 2022, then retreated by 17.56% to $59.2 million in 2023, then sank by 34.25% to $38.9 million in 2024, then soared by 30.72% to $50.9 million in 2025, then decreased by 7.07% to $47.3 million in 2026.
• The last three Operating Leases figures came in at $47.3 million (Q1 2026), $50.9 million (Q4 2025), and $53.4 million (Q3 2025), per Business Quant data.